Human and animal studies have converged to suggest that caffeine consumption prevents memory deficits in aging and Alzheimer's disease through the antagonism of adenosine A 2A receptors (A 2A Rs). To test if A 2A R activation in the hippocampus is actually sufficient to impair memory function and to begin elucidating the intracellular pathways operated by A 2A R, we have developed a chimeric rhodopsin-A 2A R protein (optoA 2A R), which retains the extracellular and transmembrane domains of rhodopsin (conferring light responsiveness and eliminating adenosine-binding pockets) fused to the intracellular loop of A 2A R to confer specific A 2A R signaling. The specificity of the optoA 2A R signaling was confirmed by light-induced selective enhancement of cAMP and phospho-mitogen-activated protein kinase (p-MAPK) (but not cGMP) levels in human embryonic kidney 293 (HEK293) cells, which was abolished by a point mutation at the C terminal of A 2A R. Supporting its physiological relevance, optoA 2A R activation and the A 2A R agonist CGS21680 produced similar activation of cAMP and p-MAPK signaling in HEK293 cells, of p-MAPK in the nucleus accumbens and of c-Fos/phosphorylated-CREB (p-CREB) in the hippocampus, and similarly enhanced long-term potentiation in the hippocampus. Remarkably, optoA 2A R activation triggered a preferential p-CREB signaling in the hippocampus and impaired spatial memory performance, while optoA 2A R activation in the nucleus accumbens triggered MAPK signaling and modulated locomotor activity. This shows that the recruitment of intracellular A 2A R signaling in the hippocampus is sufficient to trigger memory dysfunction. Furthermore, the demonstration that the biased A 2A R signaling and functions depend on intracellular A 2A R loops prompts the possibility of targeting the intracellular A 2A R-interacting partners to selectively control different neuropsychiatric behaviors.
INTRODUCTION
Recently, six longitudinal prospective studies have established an inverse relationship between caffeine consumption and the risk of developing cognitive impairments in aging and Alzheimer's disease (AD). [1] [2] [3] [4] [5] [6] [7] This is in notable agreement with animal studies, which showed that caffeine prevents memory impairments in models of AD [8] [9] [10] and sporadic dementia 11 and in other conditions affecting memory performance; 12, 13 this seems to involve the antagonism of G-protein-coupled adenosine A 2A receptors (A 2A Rs), as their selective pharmacological or genetic blockade mimic caffeine's effects. 8, 12, 14, 15 The convergence of human epidemiological and animal evidence led us to propose that A 2A Rs represent a novel therapeutic target to improve cognitive impairments in neurodegenerative disorders. The validity of this target is supported by our finding that A 2A R inactivation not only enhances working memory, 16, 17 reversal learning, 17 goal-directed behavior 18 and Pavlovian fear conditioning 19 in normal animals but also reverse memory impairments in animal models of Parkinson's disease, 20 aging 15 and AD. 8, 9, 14 Notably, pathological brain condi-tions associated with memory impairment (such as AD, stress or inflammation) are associated with increased extracellular levels of adenosine 21 and an upregulation and aberrant signaling of A 2A R. 22, 23 This prompts the hypothesis that the 'abnormal' activation of A 2A R in a particular brain region (such as the hippocampus) is sufficient to trigger memory impairment. This critical question has yet to be answered because of the inability to control forebrain A 2A R signaling in freely behaving animals with a temporal resolution relevant to behavior.
Another major unsolved question is the mechanisms operated by brain A 2A R to control memory function. In fact, A 2A R signaling is different in different cellular elements with distinct functions under various physiological vs pathological conditions. 22, 24, 25 For example, striatal and extrastriatal A 2A R exert opposite control of DARPP-32 phosphorylation, 26 c-Fos expression, 26 psychomotor activity 26, 27 and cognitive function. 19 Receptor-receptor heterodimerization has been postulated to contribute to the complexity of A 2A R signaling. 28 Additionally, recent biochemical studies identified six G-protein-interacting partners (GIP) linked to the intracellular C-terminal tail of A 2A R, 29, 30 which raises the intriguing possibility that the interaction of A 2A R intracellular domains with different GIPs may dictate the biased A 2A R signaling in different cells. However, the inability to control intracellular GPCR signaling in vivo in a precise spatiotemporal manner has prevented translation of in vitro profiles of A 2A R signaling into behavior in intact animals.
To determine if the abnormal activation of A 2A R signaling in the hippocampus is sufficient to impair memory function in freely behaving animals and to begin elucidating the nature of the biased A 2A R signaling in different brain regions, we have developed a chimeric rhodopsin-A 2A R protein (optoA 2A R): this merges the extracellular and transmembrane domains of rhodopsin conferring light responsiveness and the intracellular domains of A 2A R conferring specific A 2A R signaling, to investigate the biased A 2A R signaling in defined cell populations of freely behaving animals in a temporally precise and reversible manner. 31 Furthermore, the selective retention of only the intracellular domains of A 2A R in optoA 2A R chimera permits a critical evaluation of its particular role controlling the biased A 2A R signaling. After validating the specificity and physiological relevance of lightinduced optoA 2A R recruitment of A 2A R signaling in human embryonic kidney 293 (HEK293) cells, mouse brain slices and in freely behaving animals, we exploited its unique temporal and spatial resolution to provide direct evidence that the activation of intracellular A 2A R signaling selectively in the hippocampus is sufficient to recruit cAMP and phosphorylated-CREB (p-CREB), and alter synaptic plasticity and memory performance. Our findings also provide a direct demonstration that the intracellular control of the biased A 2A R signaling in striatal and hippocampal neurons triggers distinct signaling and behavioral responses.
MATERIALS AND METHODS

Design and construction of the optoA 2A R vector
We have developed a chimeric protein optoA 2A R by replacing the intracellular domain of rhodopsin with those of the A 2A R (Figure 1a ). We first aligned the conserved residues of the sequence of the A 2A R (NCBI accession no. NM_000675.4) with the bovine rhodopsin (NCBI accession no. P02699), and identified the intracellular loops 1, 2 and 3 of A 2A R to be exchanged with the intracellular loops of rhodopsin ( Figure 1a ). Then, we constructed a fusion gene encoding a chimera (optoA 2A R) by replacing the intracellular loops 1, 2 and 3 and the C terminal of rhodopsin with those of A 2A R and by adding the C-terminal sequence of bovine rhodopsin (TETSQVAPA) to the C terminal of optoA 2A R. Lastly, codon-optimized sequences of optoA 2A R were fused to the N terminus of mCherry (with its start codon deleted) with a linker (5′-GCGGCCGCC-3′) for fluorescence detection of optoA 2A R in cells and tissues. The optoA 2A R construct was cloned into a pcDNA3.1 vector at the EcoRI-Xhol sites.
Transfection and detection of optoA 2A R in HEK293 cells HEK293FT cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the Invitrogen protocols, and the red fluorescence of mCherry was detected 48 h after transfection. To study optoA 2A R signaling, all-trans-retinal (25 μM) were added and incubated at 37°C with 5% atmospheric CO 2 for 60 min. The cells were then illuminated with 500 nm light at 3 mW mm − 2 using a high-intensity fiber-coupled light source (OSL1-EC; Thorlabs, Newton, NJ, USA). The cells were then fixed with 4% paraformaldehyde for 10 min and permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS). Cells were blocked with 10% normal goat serum and incubated with anti-A 2A R (Santa Cruz, Dallas, TX, USA; sc-70321; 1:200) or anti-P-MAPK antibodies (Cell Signalling, Danvers, MA, USA; 1:200) overnight at 4°C. After extensive washes with phosphate buffer saline, cells were incubated with Alexa Fluor 488-conjugated secondary antibodies (Molecular Probes, Eugene, OR, USA) for 60 min at room temperature.
Assessment of optoA 2A R signaling in HEK cells
For bioluminescent assay, HEK293 cells, kept in 96-well plates, were illuminated (500 nm, 3 mW mm −2 ) for 60 sec. The cells were then lysed 30 min after cessation of light illumination to analyze cAMP using cAMP-Glo™ assay (Promega, Madison, WI, USA), cGMP by HTRF cGMP assay and IP1 by HTRF IP1 assay kit (CisBio, Sunnyvale, CA, USA.). For western blot, cells were isolated at 10 min after light illumination, using a PARIS Kit (Invitrogen). Equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% gels) and transferred onto an Immobilon-P PVDF membrane (Millipore, Billerica, MA, USA). The membranes were blocked for 1 h in Tris-buffered saline with Tween-20 (TBS-T, pH 7.6) containing 5% non-fat dry milk powder and thereafter incubated overnight at 4°C with antibodies against mitogen-activated protein kinase (MAPK, Danvers, MA, USA) (Cell Signalling, 1:500), phospho-MAPK (p-MAPK) (Cell Signalling; 1:500) or A 2A R (Santa Cruz; 1:1000). The membranes were then probed with different conjugated secondary antibody (Vector Laboratories, Burlingame, CA, USA; 1:3000) at room temperature for 90 min, followed by washing in TBS-T.
Viral production
Recombinant AAV vectors were constructed with a transgene cassette encoding CaMKIIα promoter by cloning the optoA 2A R-mCherry into pAAV-CaMKIIα-eNpHR 3.0-EYFP (Addgene, Cambridge, MA, USA) using BamHI/ HindIII assisted by GeneScript (Piscataway, NJ, USA). Viral particles were packaged and purified by vector core at the University of North Carolina (Chapel Hill, NC, USA) for serotype 5, and titers were 1.5 × 10 12 particles per ml. The AAV5-CaMKIIα-mCherry was purchased from the University of North Carolina at Chapel Hill as 'control' virus with a titer of 2.0 × 10 12 particles per ml.
Animals
All procedures were in accordance with the National Institutes of Health Guide and with EU guidelines for the care and use of laboratory animals and approved by the IACUC at the Boston University School of Medicine (Boston, MA, USA; AN no.14684) and by University of Coimbra (Coimbta, Portugal; ORBEA-78-2013 ethical approval). C57BL/6 mice at 11-13 weeks old (weighing 24-28 g) were used in the study. The A 2A R knockout mice on a C57BL/6 background were described previously. 32 Animal surgery: CNS injection and cannulas implantation Animals were anesthetized with Avertin (10 ml kg − 1 intraperitoneally). Under a stereotactic frame, a midline scalp incision was made and ã 1 mm diameter craniotomy was drilled to the right nucleus accumbens (NAc; AP, +1.1 mm; ML, ± 1.4 mm; DV, +4.5 mm) or the hippocampus (AP, − 2.2 mm; ML, ± 1.5 mm; DV, +2.3 mm). To express optoA 2A R in neurons of the NAc or hippocampus, we injected 1.0 μl of AAV5-CaMKIIα-optoA 2A R-mCherry virus or 0.75 μl of AAV5-CaMKIIa-mCherry ('control') virus at 0.1 μl − 1 . To activate the endogenous A 2A R in the NAc and hippocampus, we injected 2.0 μl of the A 2A R agonist CGS21680 (0.5 μg μl − 1 ) at 0.1 μl min − 1 using an automated syringe pump using a beveled 33-gauge needle. Following the injection, the needle was left for 5 min to allow the drug diffusion. The mice were killed after 15 min and 1 h after injection and processed for immunohistochemistry. We also bilaterally implanted guide cannulae (Plastics One, Roanoke, VA, USA) on the skull through the craniotomy, to bilaterally target the two hippocampi or the two NAc, which were secured using dental cement (Lang Dental, Wheeling, IL, USA). Animals were allowed to recover for at least 2 weeks before the experiment.
Electrophysiological recordings of synaptic plasticity in hippocampal slices
The experiments were carried out as described previously. 33 The hippocampus was dissected in an ice-cold Krebs solution and slices (400 μm) were prepared with a McIllwain chopper. Individual slices were transferred to a submersion recording chamber (1 ml capacity) and continuously superfused at a rate of 3 ml min − 1 with gassed Krebs solution (composition in mM: NaCl 124, KCl 3, NaH 2 PO 4 1.25, glucose 10, NaHCO 3 Optogenetic activation of optoA 2A R signaling in the brain A 200 μm core fiber (ThorLabs, Newton, NJ, USA) was used for optical stimulation via a patch cable connected to a 473 nm DPSS laser (100 mW; Shanghai Laser & Optics Century, Shanghai, China). The power density at the fiber tip was~3-5 mW mm −2 and light was delivered with 50 ms pulse width. For assessment of optoA 2A R signaling, mice were killed following 10 min optical stimulation. For behavior assessments, optical stimulation was delivered specifically according to different behavioral test (see below).
Behavioral tests
For the open-field test, mice were placed in the center of a white, dimly light open-field chamber (40 × 40 cm 2 ) and allowed to freely explore the environment. The center of the open-field was defined as 410 cm apart from all four walls. 'Off-On-Off' episodes of light stimulation were used and each block lasted 5 min, for a total of 15 min. Locomotor activity was detected with a video camera and analyzed with ANY-maze Video Tracking System (Stoelting, Wood Dale, IL, USA). The Y-maze test for recognition memory task was based on exploration of novelty as described previously. 34 The test consisted of two trials, separated by a 1-h time interval. During the first trial (acquisition phase), one arm of the Y-maze was closed and mice were allowed to explore the remaining two arms for 10 min with light 'OFF', with several visual clues on the walls of the room. During the second trial (retrieval phase), the mice had access to the three arms for a 5-min period with light 'ON'. During this period, the time spent in each arm and the total locomotor activity of each mouse was measured by a video-tracking system (Smart; Bioseb Chaville, Chaville, France). 
Immunohistochemistry
Preparations of total membranes and synaptosomes
Total membranes and synaptosomes from the hippocampus were prepared using sucrose/Percoll differential centrifugations, as described previously. 35 Briefly, two mouse hippocampi were placed in ice-cold 0.32 M sucrose solution and instantly homogenized with a Teflon homogenizer. After centrifugation at 3000 g for 10 min, the supernatant was collected and divided to prepare synaptosomes or total membranes. To prepare total membranes, the supernatant was centrifuged at 28000 g for 60 min and the pellet was collected. To prepare synaptosomes, the supernatant was centrifuged at 14 000 g for 12 min and the pellet was resuspended in 1 ml of a solution of 45% (v v − 1 ) Percoll in Krebs solution. After centrifugation, the top layer (synaptosomal fraction) was removed and washed with 1 ml ice-cold Krebs solution. The synaptosomes or total membranes were further resuspended in radioimmunoprecipitation assay buffer supplemented with a cocktail of protease inhibitors (Roche, Basel, Switzerland) for western blot analysis or in Krebs solution for immunocytochemical analysis.
Western blot analysis
Western blot analysis was carried out as described previously. 35 Briefly, after determining the amount of protein, total membrane or synaptosomal samples were diluted with five volumes of sodium dodecyl sulfatepolyacrylamide gel electrophoresis buffer. These diluted samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% with a 4% concentrating gel) under reducing conditions and electrotransferred to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, US). After blocking for 1 h at room temperature with 5% milk in Tris-buffered saline (pH 7.6) containing 0.1% Tween-20 (TBS-T), the membranes were incubated overnight at 4°C with a rabbit anti-A 2A R antibody (1:500, 05-717; Millipore). After three washing, the membranes were incubated with horseradish peroxidase goat anti-mouse secondary antibody (1:1500; Pierce, Rockford, IL, USA) in TBS-T during 120 min at room temperature. After three washes, the membranes were incubated with Luminata Forte (Millipore) during 5 min and then analyzed with a VersaDoc 3000 (Bio-Rad, Amadora, Portugal) to quantify A2AR immunoreactivity as well as mCherry fluorescence. The membranes were then reprobed and normalized for α-tubulin (1:20 000; Sigma, St. Louis, MO, USA) immunoreactivity.
Immunocytochemistry of synaptosomes
The immunocytochemical analysis of hippocampal synaptosomes, to detect the presence of optoA 2A R in glutamatergic terminals, was carried out as reported previously. 36 The synaptosomes were placed onto coverslips coated with poly-D-lysine, fixed with 4% paraformaldehyde in PBS for 15 min and washed two times with PBS. The synaptosomes were permeabilized in PBS with 0.2% Triton X-100 for 10 min and then blocked for 1 h in PBS with 3% bovine serum albumin and 5% normal bovine serum. The synaptosomes were incubated overnight at 4°C with either a mouse anti-A 2A R antibody (1:500; 05-717; Millipore) or with a guinea-pig vesicular glutamate transporters type-1 antibody (1:2500; 135304; Synaptic Systems, Göttingen, Germany), followed by incubation of donkey Alexa Fluor-488-conjugated anti-mouse IgG (alone) and goat Alexa Fluor-488conjugated anti-guinea-pig IgG (1:1000; Molecular Probes). The colocalization of vesicular glutamate transporters type-1 or A 2A R immunoreactivities with mCherry fluorescence was examined under a Zeiss Imager Z2 fluorescence microscope (Zeiss, Gottingen, Germany) and analyzed with ImageJ 1.37v software (NIH, Bethesda, MD, USA), as described previously. 37 
Statistics
Results are presented as mean 
RESULTS
Light activation of optoA 2A R specifically recruits A 2A R signaling in HEK293 cells
We engineered a light-activated chimeric protein able to recruit A 2A R signaling, optoA 2A R, by replacing the intracellular domains of rhodopsin with those of A 2A R (Figure 1a ). At 24 h after transfecting HEK293 cells with optoA 2A R, we observed a single band with a 80 kDa molecular weight, expected for optoA 2A R (Figure 1b ), using an A 2A R antibody targeting the third intracellular loop of A 2A R. We also detected the red fluorescence of mCherry, included in the optoA 2A R construct, largely restricted to the cell surface (Figure 1c ), similar to that obtained using the A 2A R antibody. A 2A R activate the G S /G olf -cAMP pathway as well as MAPK pathway in a G S -independent manner. 25 Light stimulation of HEK293-optoA 2A R cells (for 60 s) increased p-MAPK, in contrast with the weak p-MAPK immunoreactivity in light-stimulated cells transfected with the pcDNA3.1 vector (Figure 1d ), which was confirmed by western blot (Figure 1e ). Light stimulation of HEK293-optoA 2A R cells also increased cAMP levels by twofold (immunoassay after 20 min), compared with non-stimulated HEK293-optoA 2A R cells and with light-stimulated cells transfected with pcDNA3.1 (Figure 1f ; P o 0.001, two-way ANOVA). Thus, optoA 2A R specifically recruits the two parallel A 2A R signaling pathways, namely G S -cAMP and MAPK signaling, in HEK293 cells.
Supporting the specificity of optoA 2A R signaling, light stimulation of HEK293-optoA 2A R cells induced cAMP and p-MAPK signaling (Figures 1e and f) but did not affect either cGMP (the rhodopsin transducing system; Figure 1g ) or IP1 production (a degradation product of IP3, associated with G q signaling; Figure 1h ). Further reinforcing the selectivity of optoA 2A R to trigger cAMP accumulation, a Ser400Ala point mutation in an A 2A R phosphorylation site critical for A 2A R-D 2 R receptor interaction, 38 but not a Thr324Ala point mutation in an A 2A R phosphorylation site critical for short-term desensitization, 30 stimulation in the hippocampus significantly increased c-Fos expression specifically in the optoA 2A R-expressing cells underneath the cannula (Figure 2f ), whereas optoA 2A R activation in NAc markedly induced p-MAPK but not c-Fos (Figure 2g ). (Figure 3a) , with a density in synaptosomes similar to that detected in total membranes (n = 3, P40.05, Student's t-test). Furthermore, the immunocytochemistry analysis of purified synaptosomes (Figure 3b ) allowed the identification of mCherry fluorescence in glutamatergic nerve terminals (i.e. immunopositive for vesicular glutamate transporters type-1) only from the hippocampus transfected with AAV-mCherry-optoA 2A R (n = 3) but not with AAV-mCherry (not shown). This indicates that optoA 2A R is present in hippocampal glutamatergic nerve terminals, where endogenous A 2A R have been identified. Additionally, we observed (Figure 3c ) that the amplitude of LTP triggered by HFS was larger upon light stimulation (5 min before HFS) of hippocampal slices expressing optoA 2A R (197.3 ± 2.9% over baseline) than without light stimulation (137.7 ± 2.0% over baseline, n = 3; P40.05, Student's t-test). By contrast, light stimulation did not modify LTP amplitude in hippocampal slices expressing only mCherry (138.9 ± 2.7% vs 142.5 ± 1.5% over baseline with or without light stimulation, respectively, n = 3; P40.05, Student's t-test) (data not shown). This enhancement upon light-induced optoA 2A R activation was similar to the impact of a pharmacological activation of endogenous A 2A R with the A 2A R agonist, CGS21680 (30 nM) (Figure 3d ) , as well as in slices from mice transfected with AAV-mCherry (Figure 3e ), as occurs in the wild-type animals. This shows that light activation of optoA 2A R can mimic an established physiological response operated by endogenous A 2A R in the hippocampus. 39 Optogenetic optoA 2A R activation in the hippocampus recruits CREB phosphorylation and impairs memory performance Two weeks after the focal injection of AAV5-(CaMKIIα promoterdriven)-optoA 2A R-mCherry (Figure 4a ), light stimulation in the dorsal hippocampus significantly increased the levels of p-CREB (Figures 4c and d ; P o 0.001, Student's t-test) specifically in the optoA 2A R-expressing neurons underneath the cannula, consistent with the A 2A R-G S -cAMP pathway as the major A 2A R signaling pathway in the hippocampus. 25 Similar to p-CREB recruitment, light stimulation significantly elevated c-Fos in the optoA 2A Rexpressing neurons in hippocampus (Figure 2f ; P o 0.001, Student's t-test), whereas it did not induce p-MAPK (Figures 4b  and d ). Thus, in hippocampal neurons, light optoA 2A R activation preferentially stimulates the cAMP-PKA pathway, leading to p-CREB and c-Fos expression, without significant effect on the p-MAPK pathway.
To address the central question whether A 2A R activation in the hippocampus is sufficient to impair memory performance, we tested if triggering hippocampal optoA 2A R signaling affected spatial reference memory performance using a two-visit version of the Y-maze test. Light optoA 2A R activation in the hippocampus during the 5-min testing period reduced about twofold the time spent in the novel arm compared with mice transfected with AAV-mCherry (control) only (Figure 4e ; Po 0.001, Student's t-test). These short-term reference memory impairments were not due to changes in locomotion as gauged by the unaltered total distance travelled in the Y-maze (Figure 4f ). Thus, transient activation of optoA 2A R in a set hippocampal neurons is sufficient to recruit p-CREB signaling and deteriorate memory performance.
Light optoA 2A R stimulation in NAc recruits MAPK phosphorylation and selectively modulates motor activity We next examined the impact of light optoA 2A R activation in the NAc and the hippocampus on the two A 2A R signaling pathways (p-CREB and p-MAPK). As GPCR can produce a biased signaling simply due to different receptor levels, we used the same CaMKIIα promoter to drive similar levels of optoA 2A R expression in hippocampal and striatal neurons, 40, 41 to eliminate different optoA 2A R expression levels as a possible cause of a biased A 2A R signaling in these two forebrain regions. 42 OptoA 2A R was selectively expressed in accumbal neurons (colocalized with Neu+ neurons but not with GFAP+ astrocytes) in the core of NAc (Figure 5a ). Using enkephalin (ENK) and substance P immunostaining to identify the indirect and direct pathway neurons, 43 we found that optoA 2A R was expressed in both ENK-(52%) and SP-containing (43%) neurons in NAc (Figure 5b) . Importantly, light activation of optoA 2A R in NAc for 5 min markedly increased p-MAPK (Figures 5d and e ; P o 0.001, Student's t-test), with little induction of p-CREB and c-Fos ( Figures  5c, e and 2g) . Thus, the activation of A 2A R signaling by optoA 2A R in NAc preferentially involved the MAPK pathway rather than the cAMP-PKA-mediated c-Fos/CREB pathway.
In parallel with the preferential activation of p-MAPK signaling, light optoA 2A R activation in NAc for 5 min did not affect memory performance in the modified Y-maze test (Figure 5f ; P = 0.276, Student's t-test), but robustly increased locomotor activity (83% increase of travelled distance in the Y-maze, Figure 5g , and in the open-field test) (for AAV vectorxbehavioral phase, F(1,45) = 18.68, P o0.001, two-way ANOVA). The observed motor stimulant effect resulting from optoA 2A R activation in the NAc, instead of a motor depression observed upon accumbal administration of CGS21680, 44, 45 was expected in view of the expression of optoA 2A R in both striatopallidal and striatonigral neurons using the CaMKIIα promoter 41, 42 (rather than the selective expression of endogenous A 2A R in striatopallidal neurons prompted by the A 2A R promoter 46 ). This pitfall was however essential to circumvent the confounding effect of a 20-fold differential expression of A 2A R in these two brain regions as a possible cause for the biased A 2A R signaling. Overall, the present findings show that A 2A R trigger a biased A 2A R signaling in different forebrain regions (cAMP in the hippocampus and p-MAPK in the NAc) in parallel with an impact on distinct behaviors (memory in the hippocampus and locomotion in NAc).
DISCUSSION
The development and validation of the optoA 2A R approach to mimic endogenous A 2A R signaling allowed the novel conclusion that the recruitment of A 2A R signaling in the dorsal hippocampus is sufficient to trigger a selective memory deficit. This is in accordance with the imbalance of the local extracellular adenosine levels 21 and upregulation of A 2A R in animal models of aging, 47 sporadic dementia 11 and AD, 10 as well as in the human AD brain, 48 namely in hippocampal nerve terminals, 12,13 a situation that was mimicked by hippocampal optoA 2A R expression under the control of the CaMkIIα promoter. Indeed, optoA 2A R was detected in hippocampal synaptosomes, namely in glutamatergic synapses where endogenous A 2A R are identified and upregulated upon aging and neurodegeneration. This provides an anatomical basis for optoA 2A R control of p-CREB signaling, synaptic activity and memory performance. Indeed, the light activation of optoA 2A R in hippocampal slices mimicked a well-established physiological response operated by endogenous A 2A R, the control of hippocampal LTP. 39 Furthermore, optoA 2A R activation in the hippocampus triggers CREB phosphorylation and impairs memory performance. These findings are consistent with the canonical cAMP/PKA pathway activated by hippocampal A 2A R 25 and with the established role of CREB phosphorylation controlling synaptic plasticity and long-term memory 49 through neuronal excitability and transcription, and with specific deficits of memory retrieval observed in mice expressing a time-controlled active CREB variant. 39 This ability of hippocampal optoA 2A R activation in glutamate synapses to control memory dysfunction and its purported neurophysiological correlate LTP, decisively strengthens the relation between A 2A R and memory performance that had so far largely relied on the demonstration that A 2A R blockade alleviated memory dysfunction. 8, 9, 12, 14, 15 Furthermore, this ability to place A 2A R functioning as a sufficient factor to imbalance memory bolsters the rationale to probe the therapeutic effectiveness of A 2A R antagonists to manage memory impairment. 22, 23 This notion is further warranted by the striking convergence of epidemiological [1] [2] [3] [4] [5] [6] [7] and animal [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] evidence supporting the therapeutic benefit of caffeine and A 2A R antagonists to improve cognition. This aim should be facilitated by the safety profile of A 2A R antagonists, tested in over 3000 parkinsonian patients. 22 The design of optoA 2A R also allowed identifying a critical role solely attributable to the intracellular domains of A 2A R to dictate the biased A 2A R signaling and function in neurons of different brain regions. Contrary to the widely accepted view that ligandreceptor interactions are the molecular basis directing the biased GPCR signaling, the distinct molecular and behavioral responses obtained upon optoA 2A R activation in different brain regions show that they are only dependent on an intracellular mechanism probably related with the differential association with different GIPs in different cell types. In fact, the cell-specific expression of intracellular GIPs provides a rich molecular resource 50 whereby A 2A R signaling in the brain is specifically wired according to the needs of each cell type. In particular, the long and flexible A 2A R C terminus 29 contains several consensus sites (e.g. YXXGφ) 30 required for MAPK activation, 51 interaction with BDNF receptors (TrkB), 52 with FGF, 53 p53, 54, 55 with a large set of downstream signaling effectors such as G proteins, GPCR kinases, arrestins and with at least six GIPs (actinin, calmodulin, Necab2, translinassociated protein X, ARNO/cytohesin-2, ubiquitin-specific protease-4). 29 Thus, targeting A 2A R intracellular domains offers an additional layer of selectivity to manipulate A 2A R signaling that is not attainable only by the ligand-receptor interaction. Thus, selectively targeting A 2A R intracellular domains and their interacting GIPs in specific brain regions emerges as a novel strategy to obtain therapeutic effects with minimal side effects, as achieved with transmembrane peptides to disrupt specifically the intracellular interaction between NMDA receptors and PSD95 56, 57 and between 5-HT2c-PENT. 58 If the critical interaction between intracellular domains of A 2A R and GIPs are general features of GPCRs, the 'optoGPCR' approach targeting intracellular domains of GPCRs may represent a novel drug discovery strategy for the largest protein superfamily in the human genome.
The significance of these novel insights is decisively strengthened by the demonstrated specificity and rapid induction of the optoA 2A R signaling. The specificity of optoA 2A R signaling is supported by the selective optogenetic induction of cAMP and MAPK signaling without affecting cGMP (rhodopsin) and IP3 (G q ) signaling and by the mutational analysis demonstrating that optoA 2A R signaling is specifically attributed to the unique aminoacid composition of the A 2A R C terminus. Moreover, the comparable activation of A 2A R signaling in HEK293 cells and the indistinguishable pattern of the biased A 2A R signaling in the NAc and the hippocampus, as well as the similar enhancement of hippocampal LTP triggered by optoA 2A R and CGS21680 supports that optoA 2A R signaling largely captures the physiological function of the native A 2A R. Different from opsin-based optogenetics, opto-A 2A R signals through GPCR signaling allows a control of intracellular A 2A R signaling by light, which we now report to involve a rapid induction, consistent with similar rapid physiological response (T on1/2 =~1 s) of other GPCR light-activated chimera. Thus, the temporal and spatial control of specific A 2A R signaling afforded by optoA 2A R in freely behaving animals paves the way to probe the role of A 2A R in defined forebrain circuits responsible for behaviors ranging from motor control, fear, addiction, mood or decision making. [59] [60] [61] 
